OBI Pharma to Showcase Research Achievements and Cutting Edge ADC Platform Technology Frequent Speaking Engagements at Prestigious International Conferences

OBI Pharma (4174.TWO), as an emerging leader in the development of novel antibody-drug conjugates (ADCs) and new platform technology, is increasingly recognized on the global stage. In the upcoming six months, the company has been invited to present at several renowned international conferences, where it will share its expertise in ADC drug development and the advancements of its innovative technology platforms.